Document is current

Article History

Accepted: 15 January 2023

First Online: 30 January 2023

Declarations

:

: Deborah DeCamillo has no conflict of interest and no relevant financial or non-financial interests to disclose. Brian Haymart declares that he has no conflict of interest and no relevant financial or non-financial interests to disclose. Xiaowen Kong declares that he has no conflict of interest and no relevant financial or non-financial interests to disclose. Mona Ali declares that she has no conflict of interest and no relevant financial or non-financial interests to disclose. Scott Kaatz declares that he is a consultant for Janssen, Pfizer, BMS, Astra Zeneca, Gilead, Phase Bio, and Boston Scientific. He, his institution, receives funding from Janssen, BMS, Osmosis Research, and NIH. He is on the Board of Directors for the Anticoagulation Forum, Scientific Advisory Board for National Blood Clot Alliance, and PERT Consortium. Geoffrey Barnes declares that he receives personal fees from Bristol Meyer Squibb, Pfizer, NHLBI, Blue Cross Blue Shield of Michigan, BMS/Pfizer, Janssen, Abbott Vascular, Boston Scientific, Board of Directors for Anticoagulation Forum.

: The University’s Institutional Review Board (IRB) approved the study as an Expedited Review due to the retrospective nature of the study and all the procedures being performed were part of the routine care. The study receives yearly Continuation Review from the University’s IRB.

: Not applicable since the University’s IRB gave an Exemption due to the retrospective nature of data collection.

: Not applicable since the University’s IRB gave an Exemption due to the retrospective nature of data collection.